medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 5

<< Back

Ann Hepatol 2016; 15 (5)

Cell-based therapy to reverse advanced alcoholic liver fibrosis

Shah ND, Bataller R

Language: English
References: 15
Page: 806-808
PDF size: 109.12 Kb.


Text Extraction

Comment:

Cirrhosis is a leading cause of mortality worldwide, responsible for approximately 800,000 deaths in 2004. Liver transplantation is the only efficacious option for end-stage liver cirrhosis. However, it is limited by donor availability, surgical complications, immunological rejection and high medical costs. Because of these limitations, there has been a focus on therapies for advanced liver fibrosis.


REFERENCES

  1. World Health Organization. Global status report on alcohol and health. 2014.

  2. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18.

  3. Zhang Z, Wang FS. Stem cell therapies for liver failure and cirrhosis. J Hepatol 2013; 59: 183-5.

  4. Eom YW, Kim G, Baik SK. Mesenchymal stem cell therapy for cirrhosis: Present and future perspectives. World J Gastroenterol 2015; 21: 10253-61.

  5. Gordon MY, Levicar N, Pai M, Bachellier P, Dimarakis I, Al- Allaf F, M’Hamdi H, et al. Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells 2006; 24: 1822-30.

  6. Pai M, Zacharoulis D, Milicevic MN, Helmy S, Jiao LR, Levicar N, et al. Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis. Am J Gastroenterol 2008; 103: 1952-8.

  7. Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C, North PE, et al. Highly efficient generation of human hepatocyte- like cells from induced pluripotent stem cells. Hepatology 2010; 51: 297-305.

  8. Tumanov AV, Koroleva EP, Christiansen PA, Khan MA, Ruddy MJ, Burnette B, et al. T cell-derived lymphotoxin regulates liver regeneration. Gastroenterology 2009; 136: 694-704.

  9. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006; 98: 1076-84.

  10. Wang J, Bian C, Liao L, Zhu Y, Li J, Zeng L, Zhao RC. Inhibition of hepatic stellate cells proliferation by mesenchymal stem cells and the possible mechanisms. Hepatol Res 2009; 39: 1219-28.

  11. Suk KT, Yoon JH, Kim MY, Kim CW, Kim JK, Park H, et al. Transplantation with autologous bone marrow-derived mesenchymalstem cells for alcoholic cirrhosis: Phase 2 trial. Hepatology 2016. Doi: 10.1002/hep.28693 [Epub ahead of print].

  12. Schiff ER, Lee SS, Chao YC, Kew Yoon S, Bessone F, Wu SS, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011; 9: 274-6.

  13. Xu B, Lin L, Xu G, Zhuang Y, Guo Q, Liu Y, et al. Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B. J Gastroenterol Hepatol 2015; 30: 372-8.

  14. Akhtar E, Manne V, Saab S. Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. Liver Int 2015; 35: 30-6.

  15. Ng V, Saab S. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 923-30.




2020     |     www.medigraphic.com